Statute Details
- Title: Medicines (Prohibition of Sale, Supply and Importation) Order
- Act Code: MA1975-OR4
- Legislative Type: Subsidiary legislation (Order)
- Current Version: Current version as at 27 Mar 2026
- Authorising Act: Medicines Act (Chapter 176, Section 30)
- Commencement Date: Not stated in the provided extract (but the Order has a revised edition and subsequent amendments)
- Key Provisions:
- Section 2: Definitions
- Section 3: Restriction on sale, supply and importation of medicinal products (including expiry, safety/quality, and specified excess substances)
- Section 3(1A): Prohibition on sale, supply or importation of topical antiseptics containing mercury/mercury compounds
- Section 4: Restrictions on importation, sale and supply of Chinese proprietary medicines (microbial limits; oral vs external; fermentation carve-out)
- Section 5: Prohibition on Chinese proprietary medicines containing poisons unless conditions in Second Schedule are met and poison is naturally present
- Schedules:
- First Schedule: Poisons/allowed substances in Chinese proprietary medicines (as referenced by Section 3(1)(c) and Section 5 framework)
- Second Schedule: Poisons allowed in Chinese proprietary medicines (limits/conditions and permitted items)
- Legislative History (selected): Amended by S 8/1993, S 375/1995, S 261/1996, S 498/1998, S 711/2012, S 215/2018, S 414/2019, S 657/2019, S 563/2022
What Is This Legislation About?
The Medicines (Prohibition of Sale, Supply and Importation) Order (“the Order”) is a Singapore regulatory instrument that tightens controls over the handling of medicinal products—particularly by prohibiting the sale, supply, and importation of products that are unsafe, non-compliant with quality specifications, or contain prohibited substances. It operates as a “risk filter” at the point of market access and distribution: even where a product exists in commerce, the Order restricts what can legally be sold or supplied, and under what conditions.
In practical terms, the Order addresses two main categories of concern. First, it imposes general restrictions on medicinal products that are expired, harmful/unsafe, or outside registered/manufacturer specifications, including limits on certain substances. Second, it creates a more targeted regime for “Chinese proprietary medicines” (a defined category under Singapore’s traditional medicines framework), including microbiological limits and a poison-control mechanism tied to the Poisons Act.
For lawyers advising manufacturers, importers, wholesalers, retailers, or compliance teams, the Order is important because it creates direct prohibitions that can trigger enforcement action if breached. It also interacts with licensing and product registration regimes under the Medicines Act and related instruments, including exemptions and carve-outs that can be decisive in compliance assessments.
What Are the Key Provisions?
1) General restriction on sale, supply and importation of medicinal products (Section 3)
Section 3(1) provides that, subject to Section 3(1A), a person must not sell or supply any medicinal product to any other person if any of the listed conditions apply. The prohibited categories are:
- Expired products: the product is after the expiry date stated on the label (Section 3(1)(a)).
- Harmful/unsafe or non-conforming quality: the product is harmful or unsafe, or not in conformity with respect to strength, quality, or purity with the specification registered with the licensing authority (or, if not registered, with the manufacturer’s specification) (Section 3(1)(b)).
- Excess substances: the product contains any substances in excess of the respective quantities specified in the First Schedule (Section 3(1)(c)).
2) Mercury-containing topical antiseptics (Section 3(1A))
Section 3(1A) introduces a specific, absolute restriction: a person must not sell, supply, or import any topical antiseptic that contains mercury or any compound of mercury. This is a clear example of a targeted public-health prohibition, likely reflecting the known risks of mercury exposure and the need to prevent such substances from entering the market through common consumer-facing products.
3) Interaction with product licences (Section 3(2))
Section 3(2) provides an important carve-out: the restriction in Section 3(1)(c) (excess substances beyond First Schedule quantities) “shall not apply” to any medicinal product in respect of which a product licence has been granted and remains in force. This means that, for products with an active licence, the “First Schedule excess substances” prohibition may be displaced—at least as to that specific limb—by the licensing regime. Practitioners should therefore treat licensing status as a potentially decisive factor when assessing liability risk under Section 3.
4) Microbiological restrictions for Chinese proprietary medicines (Section 4)
Section 4 is the core compliance section for Chinese proprietary medicines. It prohibits importation, sale, or supply of such medicines when they exceed specified microbiological thresholds, with separate limits for oral consumption and external application.
Oral consumption (Section 4(1))—No person may import, sell, or supply a Chinese proprietary medicine for oral consumption if it contains any of the following:
- Total aerobic microbial count > 10 per gram or millilitre (Section 4(1)(a))
- Total yeast and mould count > 5 × 10 per gram or millilitre (Section 4(1)(b))
- Any Escherichia coli in 1 gram or 1 millilitre (Section 4(1)(c))
- Any Salmonella in 1 gram or 1 millilitre (Section 4(1)(d))
- Any Staphylococcus aureus in 1 gram or 1 millilitre (Section 4(1)(e))
External application (Section 4(2))—No person may import, sell, or supply a Chinese proprietary medicine for external application if it contains:
- Total aerobic microbial count > 10 per gram or millilitre (Section 4(2)(a))
- Total yeast and mould count > 5 × 10 per gram or millilitre (Section 4(2)(b))
- Any Pseudomonas aeruginosa in 1 gram or 1 millilitre (Section 4(2)(c))
- Any Staphylococcus aureus in 1 gram or 1 millilitre (Section 4(2)(d))
Fermentation carve-out (Section 4(3))
Section 4(3) provides a significant exception: the limits in Section 4(1)(a) and (b) (oral aerobic and yeast/mould counts) and Section 4(2)(a) and (b) (external aerobic and yeast/mould counts) do not apply to a Chinese proprietary medicine that:
- contains an active substance derived from plants, animals, or a combination; and
- has been produced by fermentation processes.
Notably, this carve-out is limited to the aerobic and yeast/mould thresholds; it does not expressly remove the prohibitions relating to the presence of specific organisms (e.g., E. coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus aureus). Practitioners should therefore treat Section 4(3) as a partial exception rather than a blanket microbiological exemption.
5) Poison control for Chinese proprietary medicines (Section 5)
Section 5 imposes a prohibition on importing, selling, or supplying any Chinese proprietary medicine that contains any item specified in the Poisons List in the Schedule to the Poisons Act, unless strict conditions are met. The structure is:
- Baseline prohibition: no Chinese proprietary medicine may contain any item in the Poisons List (Section 5).
- Permitted exception: the poison item must be (a) specified in the first column of the Second Schedule and satisfy the limit/condition in the second column; and (b) present naturally in the ingredients of the Chinese proprietary medicine.
This provision is legally significant because it links the Order to the Poisons Act’s Poisons List and then overlays a further permission framework through the Second Schedule. In other words, even if a poison is “allowed” in principle, it must also be naturally present in the ingredients and must comply with quantitative/conditional limits. For compliance teams, this requires careful ingredient sourcing documentation and analytical testing evidence.
How Is This Legislation Structured?
The Order is structured as a short, targeted instrument with a definitions section and five operative provisions, followed by schedules. The main architecture is:
- Section 1: Citation (how the Order is referred to).
- Section 2: Definitions, including the definition of “Chinese proprietary medicine” by reference to another Order under the traditional medicines framework, and “expiry date”.
- Section 3: General restrictions on sale, supply, and (via the mercury prohibition) importation of medicinal products, including expiry, safety/quality non-conformity, and excess substances, with a licensing carve-out.
- Section 4: Microbiological restrictions for Chinese proprietary medicines, distinguishing oral vs external use and providing a fermentation-related exception for certain aerobic/yeast/mould limits.
- Section 5: Poison-related prohibition for Chinese proprietary medicines, with an exception only where the poison is listed in the Second Schedule with compliant limits/conditions and is naturally present.
- First Schedule and Second Schedule: Provide the substance/poison limits and conditions that operationalise the prohibitions in Sections 3 and 5.
Who Does This Legislation Apply To?
The Order applies to “a person” in the operative provisions. Practically, this captures a wide range of market participants: manufacturers, importers, wholesalers, retailers, distributors, and any entity or individual that sells, supplies, or imports medicinal products (and specifically Chinese proprietary medicines). Because the prohibitions are framed in terms of conduct (sell/supply/import) rather than in terms of licensing status, liability risk can attach to downstream actors even if upstream compliance is imperfect.
For Chinese proprietary medicines, the Order’s restrictions apply regardless of whether the product is traditional, homoeopathic, or otherwise within the defined category—so long as it meets the definition of “Chinese proprietary medicine” and is for oral consumption or external application as described. The poison and microbiological thresholds are objective and therefore lend themselves to evidence-based enforcement (e.g., lab testing, ingredient analysis, and documentation of natural presence).
Why Is This Legislation Important?
This Order is important because it creates enforceable, product-specific prohibitions that can be triggered by objective criteria: expiry dates, microbiological counts, presence of specified organisms, and the presence of poisons beyond permitted limits. For practitioners, this means compliance is not merely a matter of “best efforts”; it is a matter of meeting measurable standards.
From an enforcement and litigation perspective, the Order’s structure supports clear factual inquiries. For example, Section 3(1)(a) turns on label expiry; Section 4 turns on microbiological test results; and Section 5 turns on whether a poison item is present and whether it is naturally present and within Second Schedule limits. These are the types of issues that can be addressed through expert evidence and documentary proof.
Finally, the licensing carve-out in Section 3(2) is a key practical nuance. It suggests that where a product licence is granted and remains in force, the “excess substances” prohibition in Section 3(1)(c) may not apply. Practitioners should therefore assess licensing status early, because it can materially affect the legal analysis and the compliance strategy (including whether to focus on licence conditions, testing regimes, and product specifications).
Related Legislation
- Medicines Act (Cap. 176) — authorising provision for the Order (Section 30)
- Poison Act (Cap. 234) — Poisons List referenced in Section 5
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order — definition of “Chinese proprietary medicine” as incorporated by Section 2
Source Documents
This article provides an overview of the Medicines (Prohibition of Sale, Supply and Importation) Order for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.